Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19458858 | 1.00 | KDM4E (0.59) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL19458668 | 0.99 | KDM4E (0.60) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL450012 | 0.94 | LMNA (0.58) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL156467 | 0.90 | KDM4E (0.58) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL9335018 | 0.87 | LTB4R (0.47) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL6744564 | 0.86 | KDM4E (0.48) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL8939333 | 0.86 | KDM4E (0.48) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL8353116 | 0.85 | KDM4E (0.61) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL28440969 | 0.85 | KDM4E (0.61) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL8660737 | 0.83 | KDM4E (0.62) | KDM4EKMT2AGAAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139670-B2 | Surface-modified zirconia nanoparticles | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130338251-A1 | SURFACE-MODIFIED ZIRCONIA NANOPARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2655257-A2 | SURFACE-MODIFIED ZIRCONIA NANOPARTICLES | 3M Innovative Properties Company (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087665-A2 | SURFACE-MODIFIED ZIRCONIA NANOPARTICLES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338251-A1 | SURFACE-MODIFIED ZIRCONIA NANOPARTICLES | PAM, CD44, CD14 | KDM4E 2128/4885KMT2A 57/4885GAA 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.